Microdosing as a tool to individualize docetaxel dosing: development of a limited sampling model

Microdosing as a tool to individualize docetaxel dosing: development of a limited sampling model - The MicroDoce study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON49402

Enrollment

Registered

2016-10-13

Start date

2017-09-14

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast- prostate and non-small cell lung cancer

Interventions

All patiënts will be administered a single intraveneous microdose(1000 microgram) docetaxel, before regular treatment with the therapeutic dosce. After the microdose and therapeutic dose blood sampl

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with breast-, prostate and non-small cell lung cancer (NSCLC), who are planned for routine treatment with docetaxel

Exclusion criteria

Exclusion criteria: Absence of informed consent

Design outcomes

Secondary

Measure	Time frame
Does not apply	—

Primary

Measure	Time frame
Pharmacokinetics of a microdoce- and a therapeutic dose docetaxel	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)